Curcuminoid Composite Formulation for Low-Dose Gut Barrier Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing turmeric extracts require high doses to effectively reduce LPS levels, endotoxemia, and intestinal lipids absorption, and there is a need for improved compositions to treat leaky gut syndrome and dyslipidemia.
Innovation Solution
A composition comprising curcuminoids, modified starch, and quillaja saponins, which reduces LPS levels and intestinal lipids absorption, and protects the intestinal barrier, using a significantly lower daily dose than standard turmeric extracts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of standard turmeric extracts are administered to reduce LPS levels and endotoxemia, then the therapeutic effect is improved, but the dosage complexity and potential side effects increase
Solution Approach 1:
The patent combines curcuminoids with acacia gum and quillaja saponins to create a composite formulation. This composite approach enhances the bioavailability and efficacy of curcuminoids, allowing therapeutic effects to be achieved at lower doses (10-20 fold reduction) compared to standard turmeric extracts alone.
Solution Approach 2:
The invention changes the chemical composition parameters by introducing specific ratios of curcuminoids (0.1-10 mg), acacia gum (1-100 mg), and quillaja saponins (0.1-10 mg). These parameter optimizations enable reduced dosing while maintaining or improving therapeutic efficacy for reducing LPS levels and endotoxemia.
2Reliability
If high doses of curcuminoids are used to reduce intestinal lipids absorption and treat dyslipidemia, then the therapeutic effect is improved, but the administration burden and potential liver stress increase
Solution Approach 1:
The composite formulation of curcuminoids with acacia gum and quillaja saponins enhances lipid metabolism regulation efficacy. The synergistic interaction among components allows effective reduction of intestinal lipid absorption and ApoB48 levels at lower doses, reducing administration burden and potential liver stress.
Solution Approach 2:
Acacia gum and quillaja saponins act as intermediaries that enhance the lipomodulatory effects of curcuminoids. These components facilitate reduced intestinal lipid absorption and improve lipid metabolism parameters, enabling therapeutic effects at lower curcuminoid doses.
3Reliability
If standard turmeric extracts are used to protect intestinal barrier integrity, then some protective effect is achieved, but very high doses are required which may cause gastrointestinal discomfort
Solution Approach 1:
The combination of curcuminoids with acacia gum (a gut-friendly fiber) and quillaja saponins creates a composite that specifically targets intestinal barrier protection. This formulation achieves effective barrier protection at lower doses by enhancing the stability and targeted action of curcuminoids in the gastrointestinal tract.
Solution Approach 2:
The formulation is designed to act locally on the intestinal barrier with enhanced specificity. The acacia gum and quillaja saponins contribute to local gastrointestinal effects that complement curcuminoid action, providing targeted protection at lower doses without causing systemic side effects.
Data Source
AI summary
The present invention relates to the use of an improved curcuminoids composition for reducing LPS levels in blood, reducing endotoxemia, protecting the integrity of the intestinal barrier, treating, decreasing and/or preventing leaky gut syndrome, reducing intestinal lipids absorption, reducing ApoB48 levels in blood and/or for in treating, decreasing and/or preventing dyslipidemia in a subject.